• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Janux Therapeutics Inc.

    4/28/26 4:22:13 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JANX alert in real time by email
    DEFA14A 1 janx_defa14a_2026_non_xb.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

     

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to §240.14a-12

    Janux Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     


     

    img51909342_0.jpg

    Janux P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Janux Therapeutics, Inc. Annual Meeting of Stockholders Thursday, June 11, 2026 1:30 PM, Pacific Time Annual meeting to be held via the internet - please visit www.proxydocs.com/JANX for more details You must register to attend the meeting online and/or participate at www.proxydocs.com/JANX For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/JANX To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 1, 2026. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 11, 2026 For Stockholders of record as of April 17, 2026 To order paper materials, use one of the following methods. Internet: www.investorelections.com/JANX Call: 1-866-648-8133 Email: paper@investorelections.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved


     

    img51909342_1.jpg

    Janux THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2 AND 3 Janux Therapeutics, Inc. Annual Meeting of Stockholders PROPOSAL 1.To elect the two nominees for Class II director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders. 1.01 Natasha Hernday 1.02 Eric Dobmeier 2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. 3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement. 4.To conduct any other business properly brought before the Annual Meeting.


    Get the next $JANX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JANX

    DatePrice TargetRatingAnalyst
    4/20/2026$14.00Overweight → Underweight
    Barclays
    4/15/2026$15.00Buy → Neutral
    UBS
    11/18/2025Peer Perform
    Wolfe Research
    9/17/2025$47.00Overweight
    Barclays
    9/10/2025$45.00Buy
    Stifel
    9/10/2025$100.00Buy
    Truist
    9/4/2025$72.00Buy
    Guggenheim
    8/19/2025$42.00Overweight
    Piper Sandler
    More analyst ratings

    $JANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Janux Therapeutics downgraded by Barclays with a new price target

    Barclays downgraded Janux Therapeutics from Overweight to Underweight and set a new price target of $14.00

    4/20/26 8:24:09 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics downgraded by UBS with a new price target

    UBS downgraded Janux Therapeutics from Buy to Neutral and set a new price target of $15.00

    4/15/26 8:07:01 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Janux Therapeutics

    Wolfe Research initiated coverage of Janux Therapeutics with a rating of Peer Perform

    11/18/25 8:24:27 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Corp. & Bus. Dev. Ofcr Doyle Janeen Noel sold $56,944 worth of shares (4,059 units at $14.03), decreasing direct ownership by 5% to 75,941 units (SEC Form 4) to satisfy tax liability

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    6/4/26 8:00:06 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vice President, Accounting Dobek Maria sold $28,878 worth of shares (2,038 units at $14.17), decreasing direct ownership by 6% to 32,270 units (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    5/13/26 8:00:09 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Go William was granted 44,000 shares (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    2/4/26 8:01:40 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

    JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011 Phase 1 study ongoing in healthy volunteers Discontinued development of JANX008 following completion of Phase 1a Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment Strong cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results fo

    5/7/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

    Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal review of the data, the Company has determined to prioritize development resources toward other pipeline opportunities. The decision to discontinue JANX008 is program-specific and does not impact the Company's broader TRACTr platfor

    4/27/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

    -JANX014 expands Janux's PSMA tumor-activated T cell engager portfolio -JANX007 is the Company's lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic in 2H2026 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux's tu

    4/16/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.

    SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    5/15/26 12:38:32 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.

    SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)

    5/12/26 11:18:42 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Janux Therapeutics Inc.

    10-Q - Janux Therapeutics, Inc. (0001817713) (Filer)

    5/7/26 4:33:47 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    3/7/25 6:05:32 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $53,700,000 worth of shares (1,200,000 units at $44.75) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    10/22/24 4:20:04 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reardon Tighe bought $4,988,643 worth of shares (849,854 units at $5.87) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    11/15/23 4:48:17 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Leadership Updates

    Live Leadership Updates

    View All

    Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

    JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011 Phase 1 study ongoing in healthy volunteers Discontinued development of JANX008 following completion of Phase 1a Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment Strong cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results fo

    5/7/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharma

    2/26/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

    Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the Company to pursue other opportunities. Dr. Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-i

    1/26/26 7:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Financials

    Live finance-specific insights

    View All

    Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

    Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica

    7/17/23 8:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:24:38 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:17:06 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:01:49 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care